% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@INPROCEEDINGS{Perneczky:283064,
      author       = {Perneczky, Robert and Hufnagel, Anna and Kurz, Carolin
                      Isabella and Tegethoff, Paulina},
      title        = {{T}he {C}ommunity {G}eneral {P}ractitioner and {G}eneral
                      {S}pecialist‐based {C}ognitive {S}creening to {I}dentify
                      {E}arly {D}ecline in {S}eniors in {G}ermany {S}tudy
                      ({COGSCREEN} 2)},
      journal      = {Alzheimer's and dementia},
      volume       = {21},
      number       = {Suppl 3},
      issn         = {1552-5260},
      reportid     = {DZNE-2025-01471},
      pages        = {e099980},
      year         = {2025},
      abstract     = {While knowledge about dementia and its causes is increasing
                      rapidly, healthcare systems remain ill-equipped to detect
                      cognitive decline in the early stages of neurodegenerative
                      diseases such as Alzheimer's disease (AD). However,
                      improving the early identification of AD in the population
                      is a prerequisite for dementia prevention and providing
                      future disease-modifying treatments for individuals most
                      likely to benefit. Subjective cognitive deficits (SCD) and
                      mild cognitive impairment (MCI) may indicate prodromal AD,
                      even in the absence of functional impairment; in conjunction
                      with an AD-typical biomarker profile, the risk of further
                      cognitive decline increases significantly. Offering
                      cognitive and biomarker investigations to individuals with
                      SCD or MCI may therefore open a window of opportunity for
                      early interventions.This project, part of the Davos
                      Alzheimer's Collaborative Healthcare System Preparedness
                      Accurate Diagnosis Project, builds on a network of general
                      practitioners (GPs) and specialists in private practice
                      (neurologists, psychiatrist and geriatricians) in Munich,
                      Germany. We will introduce participating physicians to a
                      proprietary digital cognitive test (developed by Medotrax)
                      and blood-based biomarkers (Roche p-tau217). GP-specialist
                      pairs will be allocated to four groups of centers, with
                      varying access to biomarker tests (Figure 1). The main aim
                      of the study is to assess the percentage of AD diagnoses
                      made with biomarker evidence, with secondary aims including
                      the impact of blood-based and digital investigations on
                      resource utilization and diagnostic workflows.Initial
                      experiences with designing the study protocol, learnings
                      from the recruitment of study sites and insights from study
                      participants will be presented.Currently, there is no system
                      in place for targeted, standardized identification of cases
                      with minimal cognitive decline in Germany or worldwide,
                      hindering efforts to detect neurodegenerative and other
                      causes of cognitive impairment in large segments of the
                      population. The lack of a robust approach for detecting
                      early changes with acceptable accuracy outside of specialist
                      clinics results in disappointingly low diagnostic rates. The
                      COGSCREEN 2 study will help to establish an effective and
                      efficient early diagnosis framework, embedded in a global
                      network of DAC sites.},
      month         = {Jul},
      date          = {2025-07-27},
      organization  = {Alzheimer’s Association
                       International Conference, Toronto
                       (Canada), 27 Jul 2025 - 31 Jul 2025},
      keywords     = {Humans / Cognitive Dysfunction: diagnosis / Cognitive
                      Dysfunction: blood / Alzheimer Disease: diagnosis /
                      Biomarkers: blood / Neuropsychological Tests / Germany / tau
                      Proteins: blood / Early Diagnosis / Biomarkers (NLM
                      Chemicals) / tau Proteins (NLM Chemicals)},
      cin          = {AG Dichgans},
      ddc          = {610},
      cid          = {I:(DE-2719)5000022},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)1 / PUB:(DE-HGF)16},
      pubmed       = {pmid:41445352},
      pmc          = {pmc:PMC12739319},
      doi          = {10.1002/alz70857_099980},
      url          = {https://pub.dzne.de/record/283064},
}